DNLI Q2 2019 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+154.7% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$63M-1495.4% margin

Net Income

-$58M-1390.0% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

-0.2%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$53M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$638M

Total Liabilities

$162M

Stockholders' Equity

$475M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+154.7%
Gross Profit	$4M	$2M	+154.7%
Operating Income	-$63M	-$57M	-9.4%
Net Income	-$58M	-$55M	-6.6%

Revenue Segments

Alzheimer's Disease Services

$4M100%